Omnicell Stock Surges 57.3% in a Year: What's Driving It?
OMCL shares soar 57.3% in a year as SaaS growth, Autonomous Pharmacy momentum and OmniSphere adoption boost outlook.
OMCL - Omnicell, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$57.20
DETAILS
HIGH:
$70.00
LOW:
$49.00
MEDIAN:
$55.00
CONSENSUS:
$57.20
UPSIDE:
28.80%
Stock News
Should You Buy Omnicell (OMCL) After Golden Cross?
Omnicell, Inc. (OMCL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, OMCL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
How Much Upside is Left in Omnicell (OMCL)? Wall Street Analysts Think 39.87%
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Omnicell, Inc. (OMCL) Shareholder/Analyst Call Prepared Remarks Transcript
Omnicell, Inc. (OMCL) Shareholder/Analyst Call Prepared Remarks Transcript
Omnicell, Inc. (OMCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Omnicell, Inc. (OMCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Here's Why Omnicell (OMCL) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Omnicell (OMCL) is a Great Momentum Stock: Should You Buy?
Does Omnicell (OMCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Medical Info Systems Stocks Riding the GenAI Wave in a Tough Market
Doximity, Veeva and Omnicell ride surging GenAI adoption in healthcare, tapping digital demand despite market pressure and rising cybersecurity risks.
Surging Earnings Estimates Signal Upside for Omnicell (OMCL) Stock
Omnicell (OMCL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts See a 41.19% Upside in Omnicell (OMCL): Can the Stock Really Move This High?
The mean of analysts' price targets for Omnicell (OMCL) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Omnicell Q1 Earnings & Revenues Top, Stock Up, Gross Margin Rises
OMCL posts Q1 earnings and revenue beat with surging margins and strong demand, sending shares sharply higher after results.
Investment Advisor Sells $6.6 Million Worth of Medical Solutions Stock, According to Recent SEC Filing
Omnicell provides automation and software solutions to streamline medication management for healthcare systems and pharmacies.
Here's Why Omnicell (OMCL) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer.
Why Omnicell Stock Trounced the Market on Tuesday
Analysts underestimated its ability to grow revenue and profitability in the first quarter. Management also raised certain guidance items, including adjusted profitability.
A Look at Omnicell Inc (OMCL) After 20.9% Gain -- GF Value $38.04 vs Price $45.51
On April 28, 2026, Omnicell Inc (OMCL) shares rose 20.9% to a current price of $45.51. This sharp increase follows a 52-week range where the stock has experienc
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Omnicell, Inc. (OMCL) Q1 2026 Earnings Call Transcript
Omnicell, Inc. (OMCL) Q1 2026 Earnings Call Transcript
Omnicell (OMCL) Q1 Earnings and Revenues Surpass Estimates
Omnicell (OMCL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.26 per share a year ago.
Omnicell Announces First Quarter 2026 Financial Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces First Quarter 2026 Financial Results.
Price Targets
Omnicell price target raised to $55 from $53 at Craig-Hallum
$55.00
(was $44.45)
Craig-Hallum
Omnicell price target raised to $70 from $60 at KeyBanc
$70.00
(was $44.31)
KeyBanc
Omnicell (OMCL) Reiterated at Buy by Benchmark After Investor, CEO Meet
$60.00
(was $35.10)
UBS
Omnicell price target lowered to $49 from $63 at Piper Sandler
$49.00
(was $39.08)
Piper Sandler
Omnicell (OMCL) PT Raised to $53 at BofA Securities
$53.00
(was $50.98)
UBS
Omnicell upgraded to Overweight from Sector Weight at KeyBanc
$60.00
(was $47.45)
KeyBanc
Omnicell price target raised to $52 from $43 at Wells Fargo
$52.00
(was $45.64)
Wells Fargo
Omnicell (OMCL) PT Lowered to $55 at Piper Sandler Despite Guide Raise
$55.00
(was $31.11)
Jessica Tassan
·
Piper Sandler
Omnicell upgraded to Overweight from Equal Weight at Wells Fargo
$35.00
(was $27.46)
Stan Berenshteyn
·
Wells Fargo
Omnicell price target lowered to $40 from $49 at Wells Fargo
$40.00
(was $43.37)
Stan Berenshteyn
·
Wells Fargo
Omnicell price target raised to $58 from $39 at Barclays
$58.00
(was $53.05)
Stephanie Davis
·
Barclays
Omnicell (OMCL) PT Raised to $61 at Piper Sandler
$61.00
(was $40.00)
Sean Wieland
·
Piper Sandler
Barclays Upgrades Omnicell (OMCL) to Equalweight
$39.00
(was $39.22)
Stephanie Davis
·
Barclays
JP Morgan Maintains Neutral on Omnicell, Lowers Price Target to $57
$57.00
(was $53.63)
J.P. Morgan
Omnicell price target lowered to $150 from $162 at Piper Sandler
$150.00
(was $109.12)
Jessica Tassan
·
Piper Sandler
Samsung procurement order halt 'positive' for Omnicell, says Wells Fargo
$158.00
(was $109.82)
Stan Berenshteyn
·
Wells Fargo
Piper Sandler Maintains Overweight on Omnicell, Lowers Price Target to $162
$162.00
(was $114.90)
Piper Sandler